-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Entecavir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/142217-69-4.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 142217-69-4 |
| Description | An oral antiviral drug used in the treatment of hepatitis B infection. A guanine analogue that inhhibits all three steps in the viral replication process. |
Product Information
| Synonyms | Baraclude; BMS 200475; BMS-200475; BMS200475; SQ 34676; SQ34676; SQ-34676 |
| IUPAC Name | 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one |
| Molecular Weight | 277.284 |
| Molecular Formula | C12H15N5O3 |
| Canonical SMILES | C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N |
| InChI | InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1 |
| InChIKey | QDGZDCVAUDNJFG-FXQIFTODSA-N |
| Boiling Point | 734.2ºC at 760 mmHg |
| Melting Point | 245-247 °C |
| Flash Point | 397.9ºC |
| Purity | 0.98 |
| Density | 1.8±0.1 g/cm3 |
| Solubility | In Vitro: DMSO: ≥ 44 mg/mL (158.68 mM) |
| Appearance | White to Off-White Solid |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Assay | BMS 200475 is prepared in phosphate-buffered saline (PBS) and diluted with appropriate medium containing 2% fetal bovine serum. HepG2 2.2.15 cells are plated at a density of 5 × 105 cells per well on 12-well collagen-coated plates and are maintained in a confluent state for 2 to 3 days before being overlaid with 1 mL of medium spiked with BMS 200475. |
| Complexity | 480 |
| Exact Mass | 277.11748936 |
| Index Of Refraction | 1.837 |
| In Vitro | BMS-200475 has a EC50 of 3.75 nM against HBV. It is incorporated into the protein primer of HBV and subsequently inhibits the priming step of the reverse transcriptase. The antiviral activity of BMS-200475 is significantly less against the other RNA and DNA viruses. Entecavir is more readily phosphorylated to its active metabolites than other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h. |
| In Vivo | Daily oral treatment with BMS-200475 at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduces the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks. |
| PSA | 130.05000 |
| Target | EC50: 3.75 nM (anti-HBV, HepG2 cell) |
| XLogP3-AA | -1.3 |
